Panella, R et al., (2023). MircoRNA-22 is a Key Regulator of Lipid and Metabolic Homeostasis. Int. J. Mol. Sci., 24, 12870.
Panella, R et al., (2023). Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells. Front. Pharmacol. Vol. 14.
Panella, R et al., (2023). Targeting of microRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer. Biomedicines 11(5):1470.
Yang, Z et al., (2021). MiR‐22 modulates the expression of lipogenesis‐related genes and promotes hepatic steatosis in vitro. FEBS Open Bio, 11(1), 322-332.
Lou, P et al., (2021). MiR-22 modulates brown adipocyte thermogenesis by synergistically activating the glycolytic and mTORC1 signaling pathways. Theranostics, 11(8), 3607.
Thibonnier, M et al., (2020). Metabolic and energetic benefits of microRNA-22 inhibition. BMJ Open Diabetes Research and Care, 8(1), e001478.
Hu, Y et al., (2020). miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. JHep Reports, 2(2), 100093.
Diniz, G. P et al., (2017). Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting cardiac hypertrophy. Clinical Science, 131(24), 2885-2900.
Kaur, K et al., (2015). Elevated hepatic miR-22-3p expression impairs gluconeogenesis by silencing the Wnt-responsive transcription factor Tcf7. Diabetes, 64(11), 3659-3669.
